Subscribe
2020-04-02
Pavel Kapysh / Shutterstock.com
18 February 2021Big PharmaAlex Baldwin

Amarin petitions Supreme Court to revive Vascepa patents

Irish pharmaceutical company Amarin has petitioned the Supreme Court to revive its patents on its heart medication Vascepa (icosapent ethyl).

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Amarin suffers defeat over Vascepa patents
1 April 2020   A US judge has opened the door to generic versions of heart disease drug Vascepa, after invalidating Amarin’s key patents covering the drug.
Big Pharma
Amarin vows to challenge Vascepa patent ruling
4 September 2020   Amarin has announced it will seek an en banc rehearing of a decision at the US Court of Appeals for the Federal Circuit that failed to revive its patents on heart medicine Vascepa.
Big Pharma
SCOTUS won’t resuscitate Amarin’s Vascepa patents
22 June 2021   Amarin has failed to persuade the US Supreme Court to consider reviving six patents on the heart medicine Vascepa, allowing generic drugmakers Hikma Pharmaceuticals and Dr. Reddy’s Laboratories to roll out copycat products.


Editor's picks

Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024

Editor's picks

Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024
Asia
President Xi sends message to AIPPI’s World Congress
22 October 2024
Unified Patent Court
‘Every CMS filing is painful’: Notes from a Unified Patent Court dispute
26 September 2024
Unified Patent Court
Interview: Klaus Grabinski, UPC Court of Appeal president
24 September 2024
Unified Patent Court
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers
12 September 2024
Unified Patent Court
Does the UPC offer a fresh take on patent validity?
5 September 2024

More on this story

Americas
Amarin suffers defeat over Vascepa patents
1 April 2020   A US judge has opened the door to generic versions of heart disease drug Vascepa, after invalidating Amarin’s key patents covering the drug.
Big Pharma
Amarin vows to challenge Vascepa patent ruling
4 September 2020   Amarin has announced it will seek an en banc rehearing of a decision at the US Court of Appeals for the Federal Circuit that failed to revive its patents on heart medicine Vascepa.
Big Pharma
SCOTUS won’t resuscitate Amarin’s Vascepa patents
22 June 2021   Amarin has failed to persuade the US Supreme Court to consider reviving six patents on the heart medicine Vascepa, allowing generic drugmakers Hikma Pharmaceuticals and Dr. Reddy’s Laboratories to roll out copycat products.

More on this story

Americas
Amarin suffers defeat over Vascepa patents
1 April 2020   A US judge has opened the door to generic versions of heart disease drug Vascepa, after invalidating Amarin’s key patents covering the drug.
Big Pharma
Amarin vows to challenge Vascepa patent ruling
4 September 2020   Amarin has announced it will seek an en banc rehearing of a decision at the US Court of Appeals for the Federal Circuit that failed to revive its patents on heart medicine Vascepa.
Big Pharma
SCOTUS won’t resuscitate Amarin’s Vascepa patents
22 June 2021   Amarin has failed to persuade the US Supreme Court to consider reviving six patents on the heart medicine Vascepa, allowing generic drugmakers Hikma Pharmaceuticals and Dr. Reddy’s Laboratories to roll out copycat products.

More features

President Trump 2.0: Five major areas to watch
Startup CFO’s betrayal is a lesson in preparing for the worst
Sandoz lands reduced antitrust award of $70m
New president’s to-do list: Patent bills, non-competes, USPTO director?
Sanofi subsidiary fends off $450m trade secrets case
Regulatory expert joins White & Case
Teva faces $500m fine for antitrust breaches over MS drug
UK Budget: A missed opportunity?